Biosimilars require specialized safety monitoring because they're made from living cells and can't be identical to reference biologics. Learn how adverse event reporting, traceability, and AI are shaping modern pharmacovigilance.
Biosimilars require specialized safety monitoring because they're made from living cells and can't be identical to reference biologics. Learn how adverse event reporting, traceability, and AI are shaping modern pharmacovigilance.